Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Debasish Banerjee
Research Area(s) / Expertise:
Debasish Banerjee is a consultant nephrologist with special interest in cardiovascular complications of chronic kidney disease including heart failure, sudden cardiac death and cardiac workup before kidney transplantation in chronic kidney disease patients; glomerulonephritis, kidney stone disease and diabetic nephropathy. He serves as the Clinical Subdean for St Georges Hospital and Higher… View more
Research Area(s) / Expertise: Job title: Professor of Medicine in the Division of Nephrology
Dr Navdeep Tangri is a Professor of Medicine in the Division of Nephrology at University of Manitoba, Winnipeg, CA.Dr Tangri's research programme is focused on the clinical management of patients with advanced chronic kidney disease. He developed the kidney failure risk equation (KFRE) to predict the need for dialysis in patients with chronic kidney disease. View more
EMPA-KIDNEY: Empagliflozin in Patients with Chronic Kidney Disease
Author(s): William Herrington Added: 4 months ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an… View more

Prevention & Chronic Conditions
AHA 24 Late-Breaking Discussion: The FLOW Trial
Author(s): Harriette Van Spall , Added: 3 months ago
AHA Conference 2024 — Semaglutide shows increased benefits in CKD patients based on their cardiovascular status and risk profile.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Katherine Tuttle (University of Washington, US) to discuss the effects of semaglutide in patients with chronic kidney disease (CKD).The FLOW trial (NCT03819153) is designed to assess the effect of… View more

Prevention & Chronic Conditions
CardioNerds @AHA23: Presidential Advisory on CKM Health
Author(s): Ramy Doss , Chiadi Ndumele Added: 1 year ago
AHA 2023 — CardioNerds Ambassador, Dr Ramy Doss (Nazareth Hospital, US) is joined by Dr Chiadi E Ndumele (Johns Hopkins University, US) to talk about AHA's Presidential Advisory on Cardiovascular-Kidney-Metabolic Health (CKM).The presidential advisory focuses on the cardiovascular-kidney-metabolic (CKM) syndrome, a systemic disorder connecting heart disease, kidney disease, diabetes and obesity… View more

Standards & Guidelines

Prevention & Chronic Conditions
ADA 24: FLOW Trial: Kidney Outcomes in Patients Treated with Semaglutide
Author(s): Vlado Perkovic Added: 8 months ago
ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median… View more

Prevention & Chronic Conditions
William Herrington
Research Area(s) / Expertise: Job title: Professor of Trials and Epidemiology of Kidney Disease
Professor William Herrington is an Honorary Consultant Nephrologist at Oxford Kidney Unit and the Professor of Trials and Epidemiology of Kidney Disease at the Nuffield Department of Population Health, University of Oxford.Prof Herrington earned his MD from the University of Cambridge in 2013, focusing on the impact of lowering LDL cholesterol on stroke in chronic kidney disease.He has previously… View more
ERA 23: REVEAL-CKD: Underdiagnosis of CKD
Author(s): Navdeep Tangri Added: 1 year ago
ERA 23 - In this short video from ERA 23, we are joined by Dr Navdeep Tangri (Max Rady College of Medicine, Manitoba, CA) to discuss the findings from the REVEAL-CKD Trial. REVEAL-CKD is a retrospective, multinational, non-interventional, observational study which aimed to investigate the prevalence and consequences of undiagnosed chronic kidney disease (CKD) in a cohort of 670000 participants. … View more

Prevention & Chronic Conditions
HFA 24: FINE-HEART: Design & Baseline Characteristics
Author(s): Muthiah Vaduganathan Added: 10 months ago
HFA 24 - We are joined by Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) to discuss the design and baseline characteristics of the FINE-HEART(Bayer) integrated pooled analysis of finerenone, an on-steroidal mineralocorticoid receptor (MRA) antagonist, in over 19000 patients with heart failure and CKD.FINE-HEART includes patients with type 2 diabetes, chronic kidney disease and/or… View more

Heart Failure

Prevention & Chronic Conditions
Research Area(s) / Expertise: Job title: Professor of Medicine
Prof Nikolaus Marx is a Professor of Medicine / Cardiology at RWTH University Hospital Aachen, Aachen, DE.Prof Marx's interests include cardiovascular disease in patients with comorbidities including diabetes and chronic kidney disease. View more